Grovy India Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 4, 2025, 12:06 am

Competitors of Grovy India Ltd

All Competitor Stocks of Grovy India Ltd

Quarterly Result

Last Updated: August 19, 2025, 2:20 pm

Below is a detailed analysis of the quarterly data for Grovy India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 8.25 Cr.. The value appears strong and on an upward trend. It has increased from 3.40 Cr. (Mar 2025) to 8.25 Cr., marking an increase of 4.85 Cr..
• For Expenses, as of Jun 2025, the value is 6.79 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.48 Cr. (Mar 2025) to 6.79 Cr., marking an increase of 3.31 Cr..
• For Operating Profit, as of Jun 2025, the value is 1.46 Cr.. The value appears strong and on an upward trend. It has increased from -0.08 Cr. (Mar 2025) to 1.46 Cr., marking an increase of 1.54 Cr..
• For OPM %, as of Jun 2025, the value is 17.70%. The value appears strong and on an upward trend. It has increased from -2.35% (Mar 2025) to 17.70%, marking an increase of 20.05%.
• For Other Income, as of Jun 2025, the value is 0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 0.74 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.70 Cr..
• For Interest, as of Jun 2025, the value is 0.02 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.42 Cr. (Mar 2025) to 0.02 Cr., marking a decrease of 0.40 Cr..
• For Depreciation, as of Jun 2025, the value is 0.01 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.02 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.01 Cr..
• For Profit before tax, as of Jun 2025, the value is 1.47 Cr.. The value appears strong and on an upward trend. It has increased from 0.22 Cr. (Mar 2025) to 1.47 Cr., marking an increase of 1.25 Cr..
• For Tax %, as of Jun 2025, the value is 25.85%. The value appears to be increasing, which may not be favorable. It has increased from 9.09% (Mar 2025) to 25.85%, marking an increase of 16.76%.
• For Net Profit, as of Jun 2025, the value is 1.10 Cr.. The value appears strong and on an upward trend. It has increased from 0.20 Cr. (Mar 2025) to 1.10 Cr., marking an increase of 0.90 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.82. The value appears strong and on an upward trend. It has increased from 0.15 (Mar 2025) to 0.82, marking an increase of 0.67.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 3:12 am

Growth

Last Updated: September 5, 2025, 3:40 pm

Balance Sheet

Last Updated: October 10, 2025, 4:12 pm

Below is a detailed analysis of the balance sheet data for Grovy India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 13.34 Cr.. The value appears strong and on an upward trend. It has increased from 3.33 Cr. (Mar 2024) to 13.34 Cr., marking an increase of 10.01 Cr..
• For Reserves, as of Mar 2025, the value is 7.08 Cr.. The value appears to be declining and may need further review. It has decreased from 15.52 Cr. (Mar 2024) to 7.08 Cr., marking a decrease of 8.44 Cr..
• For Borrowings, as of Mar 2025, the value is 24.62 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 11.36 Cr. (Mar 2024) to 24.62 Cr., marking an increase of 13.26 Cr..
• For Other Liabilities, as of Mar 2025, the value is 3.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.18 Cr. (Mar 2024) to 3.52 Cr., marking an increase of 3.34 Cr..
• For Total Liabilities, as of Mar 2025, the value is 48.56 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 30.39 Cr. (Mar 2024) to 48.56 Cr., marking an increase of 18.17 Cr..
• For Fixed Assets, as of Mar 2025, the value is 0.15 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Mar 2024) to 0.15 Cr., marking a decrease of 0.06 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 0.77 Cr.. The value appears to be declining and may need further review. It has decreased from 1.35 Cr. (Mar 2024) to 0.77 Cr., marking a decrease of 0.58 Cr..
• For Other Assets, as of Mar 2025, the value is 47.64 Cr.. The value appears strong and on an upward trend. It has increased from 28.83 Cr. (Mar 2024) to 47.64 Cr., marking an increase of 18.81 Cr..
• For Total Assets, as of Mar 2025, the value is 48.56 Cr.. The value appears strong and on an upward trend. It has increased from 30.39 Cr. (Mar 2024) to 48.56 Cr., marking an increase of 18.17 Cr..

However, the Borrowings (24.62 Cr.) are higher than the Reserves (7.08 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Grovy India Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 5. It has decreased from 3.00 (Mar 24) to 1.35, marking a decrease of 1.65.
• For Diluted EPS (Rs.), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 5. It has decreased from 3.00 (Mar 24) to 1.35, marking a decrease of 1.65.
• For Cash EPS (Rs.), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 3. It has decreased from 3.17 (Mar 24) to 1.40, marking a decrease of 1.77.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 15.31. It has decreased from 56.56 (Mar 24) to 15.31, marking a decrease of 41.25.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 15.31. It has decreased from 56.56 (Mar 24) to 15.31, marking a decrease of 41.25.
• For Dividend / Share (Rs.), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.10.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 19.06. It has decreased from 58.64 (Mar 24) to 19.06, marking a decrease of 39.58.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 2.20. This value is within the healthy range. It has decreased from 5.35 (Mar 24) to 2.20, marking a decrease of 3.15.
• For PBIT / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has decreased from 5.18 (Mar 24) to 2.15, marking a decrease of 3.03.
• For PBT / Share (Rs.), as of Mar 25, the value is 1.80. This value is within the healthy range. It has decreased from 3.99 (Mar 24) to 1.80, marking a decrease of 2.19.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 2. It has decreased from 3.00 (Mar 24) to 1.35, marking a decrease of 1.65.
• For PBDIT Margin (%), as of Mar 25, the value is 11.54. This value is within the healthy range. It has increased from 9.12 (Mar 24) to 11.54, marking an increase of 2.42.
• For PBIT Margin (%), as of Mar 25, the value is 11.25. This value is within the healthy range. It has increased from 8.84 (Mar 24) to 11.25, marking an increase of 2.41.
• For PBT Margin (%), as of Mar 25, the value is 9.43. This value is below the healthy minimum of 10. It has increased from 6.80 (Mar 24) to 9.43, marking an increase of 2.63.
• For Net Profit Margin (%), as of Mar 25, the value is 7.05. This value is within the healthy range. It has increased from 5.12 (Mar 24) to 7.05, marking an increase of 1.93.
• For Return on Networth / Equity (%), as of Mar 25, the value is 8.78. This value is below the healthy minimum of 15. It has increased from 5.31 (Mar 24) to 8.78, marking an increase of 3.47.
• For Return on Capital Employeed (%), as of Mar 25, the value is 12.36. This value is within the healthy range. It has increased from 8.53 (Mar 24) to 12.36, marking an increase of 3.83.
• For Return On Assets (%), as of Mar 25, the value is 3.69. This value is below the healthy minimum of 5. It has increased from 3.29 (Mar 24) to 3.69, marking an increase of 0.40.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has increased from 0.07 (Mar 24) to 0.13, marking an increase of 0.06.
• For Total Debt / Equity (X), as of Mar 25, the value is 1.21. This value exceeds the healthy maximum of 1. It has increased from 0.60 (Mar 24) to 1.21, marking an increase of 0.61.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. It has increased from 0.59 (Mar 24) to 0.64, marking an increase of 0.05.
• For Current Ratio (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has decreased from 2.89 (Mar 24) to 1.87, marking a decrease of 1.02.
• For Quick Ratio (X), as of Mar 25, the value is 0.44. This value is below the healthy minimum of 1. It has decreased from 0.50 (Mar 24) to 0.44, marking a decrease of 0.06.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 0.83, marking an increase of 0.83.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 3.32 (Mar 24) to 0.00, marking a decrease of 3.32.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 3.14 (Mar 24) to 0.00, marking a decrease of 3.14.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 96.68 (Mar 24) to 0.00, marking a decrease of 96.68.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 96.86 (Mar 24) to 0.00, marking a decrease of 96.86.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 6.32. This value is within the healthy range. It has increased from 4.48 (Mar 24) to 6.32, marking an increase of 1.84.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.86. This value is within the healthy range. It has increased from 3.51 (Mar 24) to 4.86, marking an increase of 1.35.
• For Enterprise Value (Cr.), as of Mar 25, the value is 87.43. It has increased from 50.16 (Mar 24) to 87.43, marking an increase of 37.27.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.44. This value exceeds the healthy maximum of 3. It has increased from 2.57 (Mar 24) to 3.44, marking an increase of 0.87.
• For EV / EBITDA (X), as of Mar 25, the value is 29.80. This value exceeds the healthy maximum of 15. It has increased from 28.11 (Mar 24) to 29.80, marking an increase of 1.69.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.47. This value is within the healthy range. It has increased from 1.98 (Mar 24) to 2.47, marking an increase of 0.49.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 96.67 (Mar 24) to 0.00, marking a decrease of 96.67.
• For Price / BV (X), as of Mar 25, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.06 (Mar 24) to 3.08, marking an increase of 1.02.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.47. This value is within the healthy range. It has increased from 1.98 (Mar 24) to 2.47, marking an increase of 0.49.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness